[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mohs-micrographic-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mohs-micrographic-surgery":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100622526","phase-2-efficacy-and-safety-of-topical-timolol-in-secondary-intention-surgical-wounds-healing-100622526",false,"NCT07384767","Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing","Efficacy and Safety of Topical Timolol in the Treatment of Cutaneous Surgical Wounds Left to Heal by Secondary Intention","Inclusion Criteria:\n\n1. Male or female subject of any race 18 years old or older\n2. Patient opt to heal by secondary intention healing after discussion of reconstructive options following excision\n3. Patients undergoing Mohs micrographic surgery, standard surgical excision, or electrodesiccation and curettage (ED\\&C) whose wounds are managed by secondary intention healing.\n4. Willing to send photos of ulcer at 3 week intervals with ruler measuring length by width\n5. Able to give informed consent themselves\n\nExclusion Criteria:\n\n1. Cyst excisions (due to concern for inflammation)\n2. Site shows evidence of infection (defined as a moderate or severe rating of all of the following clinical signs\u002Fsymptoms: 1) increased warmth, 2) increased pain, 3) erythema, and 4) malodorous exudate at Screening or at Randomization (Visit 1), OR total organism count \\> 1 x 105 colony forming units (CFU) from the screening visit study ulcer culture sample)\n3. Severe COPD\u002Fasthma\u002Fcardiac arrhythmia\n4. Hx of documented beta blocker allergy\n5. Cognitive impairment\n6. Has medically documented history of Human Immunodeficiency Virus (HIV)\n7. Has active malignancy on the study limb\n8. Has immunodeficiency as defined by serum IgG, IgA, and IgM less than one-half the lower limit of normal\n9. Has severe protein malnutrition as defined by serum albumin \\\u003C 2.5 g\u002FdL\n10. Has serum aspartate aminotransferase (AST, SGOT, GOT) or serum alanine aminotransferase (ALT, SGPT, GPT) levels greater than twice the upper limit of normal\n11. Has fatigue, palpitations, dyspnea, and\u002For angina at rest\n12. Has a medically documented or self-reported history, within the previous 12 months from date of Screening Visit, of alcohol or drug abuse, particularly methadone or heroin\n13. Has received previous treatment with the following during the 60 days prior to Screening: Immunosuppressive agents, radiation, chemotherapy, growth factors (epidermal growth factor, tumor necrosis factor, transforming growth factor, platelet derived growth factor, etc.)\n14. Has received previous treatment with the following during the 30 days prior to screening: the site of the study ulcer, split- or full-thickness skin graft at the site of the study ulcer, biologically-active (or engineered) cellular or acellular product(s) at the site of the study ulcer, investigational drug or device\n15. Has history of bradycardia (heart rate less than 60)\n16. Has ESR\\>70mm\u002Fhr and CRP\\>100 mg\u002FL at time of screening\n17. Has medically documented history of hypotension\u002Forthostatic hypotension and\u002For symptomatic hypotension (systolic blood pressure below 90 and diastolic blood pressure less than 60). (Note: There is no standard testing regimen protocol for orthostatic hypotension, even for patients starting on oral timolol)\n18. Currently taking asthma or COPD medications (as documented in chart)\n19. Has a medically documented diagnosis of myasthenia gravis, untreated hyperthyroidism, , Type 2, Type 3 heart block, cardiogenic shock, overt cardiac failure\n20. Female who is pregnant or refuses to use adequate contraceptive methods and is of childbearing age during the trial\n21. Prisoners, institutionalized individuals or vulnerable population","ALL","18 Years",{"count":19,"type":20},220,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this research study is to evaluate the efficacy and safety of topical timolol 0.5% for secondary intention wound healing following 1) Mohs micrographic surgery, 2) standard surgical excision, OR 3) electrodesiccation and curettage (ED\\&C). Please note that healing by secondary intention refers to when a wound heals naturally without surgical closure.\n\nTo evaluate the efficacy of topical timolol 0.5%, 220 participants will be recruited. Participants will be placed into one of two groups: The treatment group or the control group.\n\n1. The treatment group will receive a topical timolol 0.5% solution, which will be applied to their wound daily for 12 weeks.\n2. The control group will receive standard care with the addition of hydrogel, which will also be applied to their wound daily for 12 weeks.\n\nDuring this 12-week period, both groups will be required to upload photos of their wound healing to their MyChart account at weeks 3, 6, 9, and 12. These photos will be reviewed by the investigator to assess wound healing. Re-epithelialization and earlier complete wound healing will be compared between both groups to determine the efficacy of topical timolol 0.5% solution compared to the standard of care.",[26,27],"Mohs Micrographic Surgery","Excision Margin",[29,30,31,32,33],"standard surgical excision","Mohs micrographic surgery","electrodesiccation and curettage","timolol","randomized","NOT_YET_RECRUITING","2026-02-04",{"date":37,"type":38},"2026-02-09","ACTUAL",{"date":40,"type":20},"2026-06-01",{"date":42,"type":20},"2027-12-31",{"name":44,"class":45},"University of California, Davis","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100598720","hydrocolloid-dressings-for-oculofacial-plastic-and-reconstructive-wound-healing-100598720","NCT07075159","Hydrocolloid Dressings for Oculofacial Plastic and Reconstructive Wound Healing","HCD Wound Heal","Inclusion Criteria:\n\n* Patients \\>18 years of age\n* follow-up at specified intervals (1 week\u002F6 week\u002F3 months) in an office setting\n* can give informed consent\n* no patients will be excluded on the basis of gender, ethnicity, or religious background\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years of age or \\>100\n* allergy to pectin, gelatin, and sodium carboxymethylcellulose\n* adults with impaired consent capacity\n* incarcerated individuals.","100 Years",{"count":56,"type":20},20,[58],"NA","This study aims to explore the use of a hydrocolloid dressing (DuoDERM EXTRA THIN) as an alternative to the current standard of care. The dressing would be applied immediately after surgery and removed at a post-operative week 1 appointment. The dressing would eliminate the need for antibiotic ointment application and reduce the burden of post-operative care on the patient.",[61,26,62],"Wound Healing","Oculofacial Reconstruction","RECRUITING","2025-12-15",{"date":66,"type":38},"2025-12-17",{"date":68,"type":38},"2025-02-28",{"date":70,"type":20},"2026-09-01",{"name":72,"class":45},"Janice Hernandez, MD",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":73},"100588443","phase-1-topical-05-timolol-solution-for-healing-lower-extremity-wounds-100588443","NCT06941467","Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds","Efficacy of Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds","Inclusion Criteria:\n\n* Be scheduled to undergo MMS at 234 East 85th St for a skin cancer that is deemed Mohs\n* Appropriate by the Mohs surgery appropriate use criteria\n* Have an open surgical wound \\\u003C 4 cm and \\> 0.5 cm\n* Be ≥18 years of age\n* English-speaking\n* Provide a signed and dated informed consent form\n* State willingness to comply with all study procedures\n\nExclusion Criteria:\n\n* Age less than 18 years of age\n* Open surgical wound \\> 4 cm\n* If tumor clearance cannot be achieved with MMS\n* Pregnant women\n* Breastfeeding women\n* Patients who are taking oral beta-blockers (ie oral timolol, metoprolol, carvedilol, propranolol, atenolol)\n* Patients who are currently taking any of the following medications: clonidine, digoxin, methyldopa, quinidine, fluoxetine and paroxetine, bupropion\n* Patient currently taking a calcium channel blocker AND has pre-existing heart failure as defined by a reduced ejection fraction\n* Patients with pre-existing hypotension\n* Pre-existing diagnosis of sinus bradycardia\n* Pre-existing diagnosis of second or third degree atrioventricular block\n* Congestive heart failure\n* Pre-existing diagnosis of severe asthma\n* Pre-existing diagnosis of chronic obstructive pulmonary disease\n* Any known hypersensitivity to 0.5% timolol solution\n* Patients who have a wound where primary closure is feasible and desired by the patient\n* Defect size \\\u003C0.5 cm\n* Prior sensitivity or known allergy to timolol",{"count":82,"type":20},102,[84],"PHASE1","Topical timolol, a β2-Adrenergic receptor (B2AR) antagonist, has demonstrated promise in wound healing over the past several years. The majority of the literature has evaluated the use of topical timolol to shorten wound healing time in chronic wounds of non-surgical etiologies. To date, there are no prospective randomized clinical trials evaluating the role of topical timolol for shortening wound healing time in acute open surgical wounds.\n\nTherefore, the purpose of this study is to determine whether or not topical timolol solution decreases time to wound healing in patients with defects after Mohs Micrographic Surgery (MMS) that cannot be closed with sutures and are left to heal by second intent. The research team also will look to determine if there is a difference in cosmesis of wounds treated with topical timolol compared to those treated with the standard of care. The present study will primarily focus on wounds in the distal lower extremity as these are most commonly left to heal by secondary intent",[61,26],"2025-04-16",{"date":89,"type":38},"2025-04-23",{"date":91,"type":38},"2025-01-03",{"date":93,"type":20},"2026-04-01",{"name":95,"class":45},"Icahn School of Medicine at Mount Sinai"]